CN Patent

CN108912066B — 治疗活性化合物及其使用方法

Assigned to Les Laboratoires Servier SAS · Expires 2022-06-24 · 4y expired

What this patent protects

本文提供适用于治疗癌症的化合物和治疗癌症的方法，所述方法包括向有需要的受试者施用本文所描述的化合物。本文还提供本发明化合物的制备方法。

USPTO Abstract

本文提供适用于治疗癌症的化合物和治疗癌症的方法，所述方法包括向有需要的受试者施用本文所描述的化合物。本文还提供本发明化合物的制备方法。

Drugs covered by this patent

enasidenib-mesylate (ENASIDENIB MESYLATE)

Patent Metadata

Patent number: CN108912066B
Jurisdiction: CN
Classification: —
Expires: 2022-06-24
Drug substance claim: No
Drug product claim: No
Assignee: Les Laboratoires Servier SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.